EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 2.16 billion. The enterprise value is 2.30 billion.

Market Cap	2.16B
Enterprise Value	2.30B

Important Dates

The next estimated earnings date is Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.06 million shares outstanding. The number of shares has decreased by -1.74% in one year.

Current Share Class	n/a
Shares Outstanding	29.06M
Shares Change (YoY)	-1.74%
Shares Change (QoQ)	+2.86%
Owned by Insiders (%)	2.15%
Owned by Institutions (%)	8.42%
Float	12.62M

Valuation Ratios

The trailing PE ratio is 62.33 and the forward PE ratio is 32.62.

PE Ratio	62.33
Forward PE	32.62
PS Ratio	6.37
PB Ratio	10.37
P/TBV Ratio	216.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.95, with an EV/FCF ratio of -157.00.

EV / Earnings	66.17
EV / Sales	6.79
EV / EBITDA	37.95
EV / EBIT	43.55
EV / FCF	-157.00

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.76.

Current Ratio	1.23
Quick Ratio	0.45
Debt / Equity	0.76
Debt / EBITDA	2.59
Debt / FCF	-10.73
Interest Coverage	5.87

Financial Efficiency

Return on equity (ROE) is 18.23% and return on invested capital (ROIC) is 10.37%.

Return on Equity (ROE)	18.23%
Return on Assets (ROA)	8.24%
Return on Invested Capital (ROIC)	10.37%
Return on Capital Employed (ROCE)	21.20%
Revenue Per Employee	12.09M
Profits Per Employee	1.24M
Employee Count	21
Asset Turnover	0.85
Inventory Turnover	1.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +76.67% in the last 52 weeks. The beta is 0.59, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	+76.67%
50-Day Moving Average	79.44
200-Day Moving Average	66.57
Relative Strength Index (RSI)	43.50
Average Volume (20 Days)	24,051

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 338.39 million and earned 34.73 million in profits. Earnings per share was 1.19.

Revenue	338.39M
Gross Profit	140.90M
Operating Income	52.77M
Pretax Income	43.78M
Net Income	34.73M
EBITDA	59.08M
EBIT	52.77M
Earnings Per Share (EPS)	1.19

Full Income Statement

Balance Sheet

The company has 15.56 million in cash and 157.02 million in debt, giving a net cash position of -141.46 million or -4.87 per share.

Cash & Cash Equivalents	15.56M
Total Debt	157.02M
Net Cash	-141.46M
Net Cash Per Share	-4.87
Equity (Book Value)	207.96M
Book Value Per Share	7.16
Working Capital	48.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.64 million and capital expenditures -1.00 million, giving a free cash flow of -14.64 million.

Operating Cash Flow	-13.64M
Capital Expenditures	-1.00M
Free Cash Flow	-14.64M
FCF Per Share	-0.50

Full Cash Flow Statement

Margins

Gross margin is 41.64%, with operating and profit margins of 15.59% and 10.26%.

Gross Margin	41.64%
Operating Margin	15.59%
Pretax Margin	12.94%
Profit Margin	10.26%
EBITDA Margin	17.46%
EBIT Margin	15.59%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.74%
Shareholder Yield	1.74%
Earnings Yield	1.61%
FCF Yield	-0.68%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a